The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against candida albicans biofilms

Journal of Infectious Diseases

Volumn 206, Issue 11, 2012, Pages 1790-1797

  Bink, Anna ^a   Kucharíková, Soňa ^b   Neirinck, Bram ^b   Vleugels, Jef ^b   Van Dijck, Patrick ^b   Cammue, Bruno P A ^a   Thevissen, Karin ^a  

^a 3001   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; DICLOFENAC; PLACEBO; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; CATHETER; CONTROLLED STUDY; DRUG POTENTIATION; FUNGUS GROWTH; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; CATHETERS; DICLOFENAC; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; ECHINOCANDINS; RATS;

EID: 84869078432     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis594     Document Type: Article

References (22)

1. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. Our current understanding of fungal biofilms. Crit Rev Microbiol 2009; 35:340-55.
2. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46:1773-80.
3. Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 2006; 194:710-13.
4. DiDone L, Oga D, Krysan DJ. A novel assay of biofilm antifungal activity reveals that amphotericin B and caspofungin lyse Candida albicans cells in biofilms. Yeast 2011; 28:561-8.
5. Cocuaud C, Rodier MH, Daniault G, Imbert C. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J Antimicrob Chemother 2005; 56:507-12.
6. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemother 2010; 65:271-4.
7. Ghalehnoo ZR, Rashki A, Najimi M, Dominguez A. The role of diclofenac sodium in the dimorphic transition in Candida albicans. Microb Pathog 2010; 48:110-5.
8. Alem MA, Douglas LJ. Effects of aspirin and other nonsteroidal antiinflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob Agents Chemother 2004; 48:41-7.
9. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors-current status and future prospects. Eur J Med Chem 2001; 36:109-26.
10. Alem MA, Douglas LJ. Prostaglandin production during growth of Candida albicans biofilms. J Med Microbiol 2005; 54:1001-5.
11. Erb-Downward JR, Noverr MC. Characterization of prostaglandin E2 production by Candida albicans. Infect Immun 2007; 75:3498-505.
12. Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell 1997; 90:939-49.
13. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53:112-22.
14. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeast, approved standard M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
15. Ramage G, Vande Walle K, Wickes BL, López-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45:2475-9.
16. Moody JA. Synergism testing. Broth microdilution checkerboard and broth microdilution methods. In: Isenberg HD, ed. Clinical microbiology procedures handbook. Vol 1 Washington, DC: American Society for Microbiology, 1991:5.18.1-28.
17. ?i?icová M, Kucharíková S, Tournu H, et al. Candida albicans biofilm formation in a new in vivo rat model. Microbiology 2010; 156:909-19.
18. Kucharíková S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. In vivo Efficacy of anidulafungin against Candida albicans mature biofilms in a novel rat model of catheter-associated candidiasis. Antimicrob Agents Chemotherap 2010; 54:4474-5.
19. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10:121-30.
20. Kucharíková S, Tournu H, Lagrou K, Van Dijck P, Bujdáková H. Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. J Med Microbiol 2011; 60:1261-9.
21. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70:878-88.
22. Gregori C, Glaser W, Frohner IE, et al. Efg1 Controls Caspofungin- Induced Cell Aggregation of Candida albicans through the Adhesin Als1. Eukaryot Cell 2011; 10:1694-704.